Nisa Investment Advisors LLC grew its stake in shares of Editas Medicine Inc (NASDAQ:EDIT) by 221.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 71,400 shares of the company’s stock after buying an additional 49,200 shares during the quarter. Nisa Investment Advisors LLC owned approximately 0.16% of Editas Medicine worth $2,194,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of Editas Medicine by 12.5% during the second quarter. Vanguard Group Inc. now owns 2,177,146 shares of the company’s stock worth $36,533,000 after buying an additional 241,973 shares during the last quarter. State Street Corp lifted its holdings in shares of Editas Medicine by 305.4% during the second quarter. State Street Corp now owns 537,640 shares of the company’s stock worth $9,022,000 after purchasing an additional 405,022 shares during the period. Ark Investment Management LLC lifted its holdings in shares of Editas Medicine by 121.9% during the second quarter. Ark Investment Management LLC now owns 510,187 shares of the company’s stock worth $8,561,000 after purchasing an additional 280,265 shares during the period. Northern Trust Corp lifted its holdings in shares of Editas Medicine by 245.9% during the second quarter. Northern Trust Corp now owns 373,149 shares of the company’s stock worth $6,261,000 after purchasing an additional 265,273 shares during the period. Finally, American Century Companies Inc. acquired a new position in shares of Editas Medicine during the third quarter worth $7,497,000. 64.45% of the stock is currently owned by hedge funds and other institutional investors.
In other Editas Medicine news, insider Katrine Bosley sold 20,000 shares of the business’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $38.79, for a total value of $775,800.00. Following the transaction, the insider now directly owns 1,354,431 shares in the company, valued at $52,538,378.49. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew A. F. Hack sold 5,000 shares of the business’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $24.81, for a total transaction of $124,050.00. Following the completion of the transaction, the chief financial officer now owns 5,000 shares in the company, valued at $124,050. The disclosure for this sale can be found here. Over the last quarter, insiders sold 84,648 shares of company stock worth $2,687,509. Corporate insiders own 19.40% of the company’s stock.
Shares of Editas Medicine Inc (NASDAQ EDIT) traded up $0.41 during mid-day trading on Friday, reaching $33.69. 2,118,932 shares of the company’s stock were exchanged, compared to its average volume of 1,850,000. The company has a quick ratio of 10.12, a current ratio of 10.12 and a debt-to-equity ratio of 0.19. The company has a market cap of $1,530.00 and a P/E ratio of -10.40. Editas Medicine Inc has a twelve month low of $13.12 and a twelve month high of $41.60.
EDIT has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Friday, November 10th. ValuEngine lowered shares of Editas Medicine from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Cowen restated a “buy” rating on shares of Editas Medicine in a report on Tuesday, November 7th. Finally, Cann reaffirmed a “hold” rating on shares of Editas Medicine in a research note on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $30.73.
COPYRIGHT VIOLATION WARNING: This article was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://ledgergazette.com/2018/02/12/nisa-investment-advisors-llc-has-2-19-million-position-in-editas-medicine-inc-edit.html.
Editas Medicine Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.